Last reviewed · How we verify
StellaLife
StellaLife is a topical oral rinse that provides symptomatic relief and promotes healing of oral mucositis by creating a protective barrier and reducing inflammation in the oral cavity.
StellaLife is a topical oral rinse that provides symptomatic relief and promotes healing of oral mucositis by creating a protective barrier and reducing inflammation in the oral cavity. Used for Oral mucositis associated with cancer chemotherapy and radiation therapy.
At a glance
| Generic name | StellaLife |
|---|---|
| Sponsor | Stony Brook University |
| Drug class | Topical oral protective agent |
| Modality | Small molecule |
| Therapeutic area | Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
StellaLife is a proprietary formulation designed to coat and protect damaged oral tissues while delivering anti-inflammatory and antimicrobial agents. It is used to manage oral mucositis, a common and painful side effect of cancer chemotherapy and radiation therapy, by reducing pain, promoting tissue repair, and preventing secondary infections.
Approved indications
- Oral mucositis associated with cancer chemotherapy and radiation therapy
Common side effects
- Mild taste alteration
- Temporary numbness or tingling
Key clinical trials
- Protocol Efficacy of Mouthwashes in Experimental Gingivitis (PHASE4)
- Effects of StellaLife Oral Care Recovery Kit on Palatal Wound Healing After Free Gingival Graft (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- StellaLife CI brief — competitive landscape report
- StellaLife updates RSS · CI watch RSS
- Stony Brook University portfolio CI